Rolipram ( DrugBank: Rolipram )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
8	ハンチントン病	1
13	多発性硬化症／視神経脊髄炎	1

8. ハンチントン病

---

臨床試験数 : 242 /  薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01602900 (ClinicalTrials.gov)	November 22, 2011	1/12/2011	Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's Disease	An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain PDE4 Engagement, Pharmacokinetics and Safety of Single Oral Doses of GSK356278, Using 11C-(R)-Rolipram as a PET Ligand(s)	Huntington Disease	Drug: GSK356278;Drug: Rolipram	GlaxoSmithKline	NULL	Completed	22 Years	55 Years	Male	8	Phase 1	United Kingdom

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,340 /  薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00011375 (ClinicalTrials.gov)	February 2001	16/2/2001	Rolipram to Treat Multiple Sclerosis	Safety, Tolerability & Effects of Rolipram on Inflammatory Activity in the Central Nervous System in Multiple Sclerosis. A Phase II, Open Label Crossover Trial Using MRI as an Outcome Measure	Multiple Sclerosis	Drug: Rolipram	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	N/A	N/A	Both	52	Phase 2	United States